Open Access Full Text Article

CORRIGENDUM

Early Elevation of Thioredoxin-I Serum Levels Predicts 28-Day Mortality in Patients with Sepsis [Corrigendum]

Li X, Shen H, Zhou T, et al. *J Inflamm Res.* 2021;14:3837– The author. 3848.

The authors apologize for this error.

The authors have advised due to an error at the time of assembling the Tables, Table 1 on page 3841 is incorrect. The correct Table is as follows.

Table I Comparison of Baseline Clinical Characteristics Between Survivors and Non-Survivors

	Survivors	Non-Survivors	P value
Age (years)	65±16	68±13	0.172
Gender (male/female)	109/35	24/19	0.012
Coronary heart disease	45 (31.3%)	3 (30.2%)	0.899
Hypertension	38 (26.4%)	(25.6%)	0.916
Type 2 diabetes	15 (10.4%)	5 (11.6%)	0.822
Chronic renal failure	(7.8%)	4 (9.3%)	0.725
COPD	23 (16.0%)	8 (18.1%)	0.684
Length of ICU stay(days)	8 (3~21)	6 (2~22)	0.025
Survival days	28	10 (2~22)	0.000
Trx-I (ng/mL)	15.2 (2.3–789.5)	382.5 (7.5–1732.5)	0.000
Lac (mmol/L)	2.2 (0.5–11.0)	3.2 (0.9–18)	0.000
PCT (ng/mL)	4.10 (0.40–200.00)	13.9 (0.4–200.0)	0.000
CRP (mg/mL)	99.40 (7.48–200.0)	127.6 (18.6-468.0)	0.000
IL-6 (ng/mL)	74.6 (2.9–754.3)	376.3 (13.4–912.1)	0.000
∆SOFA	6 (2–18)	(3–15)	0.000
HR (beats/min)	101±22	0±33	0.033
RR (beats/min)	24±6	24 (12-40)	0.048
MAP (mmHg)	84±18	70±17	0.000
Temperature	37.5±1.0	37.8±1.3	0.000
WBCs (10 ⁹)	15.1±8.0	13.5±6.4	0.222
HCT%	32.7±9.1	31.1±7.0	0.295
PLT (10 ⁹)	172 (21.0–527.0)	130.0 (17.0–364.0)	0.025

(Continued)

Journal of Inflammation Research 2021:14 7499–7500

© 2021 Li et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-mc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Table I (Continued).

	Survivors	Non-Survivors	P value
Scr (umol/L)	96.4 (33.7–507.6)	144.0 (44.9–1477.9)	0.002
TBIL(mmol/L)	17 (3.1–122.0)	19.6 (4.6–124.7)	0.029
PaO2/FIO2 (mmHg)	187.8 (44.8–675.0)	150.2 (63.3–417.1)	0.001
GCS	12 (3–15)	9 (3–15)	0.000

Abbreviations: Trx-I, thioredoxin; Lac, lactate; PCT, procalcitonin; CRP, C-reactive protein; IL-6, interleukin-6; △SOFA, sequential organ failure assessment score; HR, heart rate; RR, respiratory rate; MAP, mean artery pressure; WBC, white blood cells; PLT, platelet; HCT, hematocrit; TBIL, total bilirubin; GCS, Glasgow Coma Score.

Journal of Inflammation Research

Publish your work in this journal

The Journal of Inflammation Research is an international, peerreviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular

mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peerreview system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-inflammation-research-journal

https://doi.org/10.2147/JIR.S351869

Dovepress